BTIG Research upgraded shares of CrowdStrike (NASDAQ:CRWD – Free Report) from a neutral rating to a buy rating in a research ...

Ovid Therapeutics (NASDAQ:OVID – Get Free Report) had its price objective cut by BTIG Research from $5.00 to $4.00 in a ...

BTIG upgraded CrowdStrike (CRWD) to Buy from Neutral with a $431 price target With the July 19, 2024 IT outage now eight months in the ...

In a report released yesterday, Michael Gorman from BTIG maintained a Buy rating on NETSTREIT (NTST – Research Report), with a price target of ...

Fintel reports that on March 25, 2025, BTIG upgraded their outlook for CrowdStrike Holdings (NasdaqGS:CRWD) from Neutral to ...

Ally Financial (NYSE:ALLY) was trading lower after BTIG analysts downgraded the stock, citing that meeting the ROE and EPS targets will be difficult for the auto lender.

Shares of CrowdStrike ( CRWD 3.34%) surged higher on Monday. The company's stock had gained 3.7% as of 10:50 a.m. ET but had ...

BTIG analyst Gray Powell issued a buy rating for CrowdStrike, upgrading it from neutral, and set a $431 per share price ...

Key Takeaways The S&P 500 edged 0.2% higher on Tuesday, March 25, 2025, despite a report showing that consumer confidence ...

Humacyte, Inc.'s stock fell 25% amid $50M fundraising and safety concerns on FDA-approved Symvess. Click for this updated ...

We recently published a list of Top 10 Penny Stocks That Will Skyrocket. In this article, we are going to take a look at ...

It hasn’t been long since DeepSeek released its efficient yet low-cost models, causing a frenzy in the tech world.